Trade DNLI stock anytime, 24x5 in Singapore
Regulated by
Monetary Authority of Singapore (MAS)
Trusted by
400,000+ users
Denali Therapeutics Inc. (DNLI) is trading at US$19.72, down 2.04% today as of Sep 18, 16:00 EDT. The company has a market capitalisation of US$3.98B. Over the past 52 weeks, DNLI has traded between US$12.58 and US$27.30. On Syfe you can trade DNLI with $0 commission and add it to your watchlist.
| Previous close | US$20.13 |
|---|---|
| Market cap | US$3.98B |
| 52-week range | US$12.58 – US$27.30 |
| Volume | 2.96M |
| Exchange | US |
Add to Watchlist
Set Price Alert
Denali Therapeutics Inc.
Denali Therapeutics, Inc. is a biopharmaceutical company, which engages in the development and commercialization of a portfolio of product candidates for neurodegenerative diseases. Its product pipeline includes LRRK2, RIPK1, TREM2, and Tau. The company was founded by Ryan J. Watts, Marc Tessier-Lavigne, and Alexander Schuth on October 14, 2013 and is headquartered in San Francisco, CA.
Year: 2017
UBS Adjusts Price Target on Denali Therapeutics to $34 From $25, Maintains Buy Rating
Aug 7, 2:28 PM · MT Newswires
Wedbush Adjusts PT on Denali Therapeutics to $27 From $26, Maintains Outperform Rating
Aug 7, 10:33 AM · MT Newswires
-- Earnings Flash (DNLI) Denali Therapeutics Posts Q2 Loss of $0.68, vs. FactSet Est of $0.51 Loss
Aug 6, 9:30 PM · MT Newswires
Denali Therapeutics Inc. (DNLI) stock is trading at US$19.72, -2.04% from the previous close of US$20.13.
The market cap for Denali Therapeutics Inc. (DNLI) stock is approximately US$3.98B.
The 52-week high for Denali Therapeutics Inc. (DNLI) stock is US$27.30.
The 52-week low for Denali Therapeutics Inc. (DNLI) stock is US$12.58.
Denali Therapeutics Inc. (DNLI) does not currently pay a dividend.
Stay on top of DNLI
Price moves, news and earnings — straight to your inbox.
Est. order value
US$0.00
Snapshot
Popular Stocks in Singapore
